UEGW 2023 Highlights Podcast

In this episode [12.04], Medicom’s correspondent covers 6 presentations from the United European Gastroenterology Week (UEGW 2023), held in Copenhagen, Denmark, from 14-17 October 2023. International Headache Congress (IHC 2021), held virtually from 8-12 September 2021.
The topics discussed are:

1. Primary results from MAESTRO-NASH trial: resmetirom efficacious for NASH
   Resmetirom proved efficacious in the treatment of non-alcoholic steatohepatitis and has shown improvement in fibrosis. Together with the agent's acceptable safety profile, resmetirom candidates as a useful oral therapy for patients with NASH.
2. ARTEMIS-UC: New kid in town for UC
   In a phase 2 trial, induction therapy with the investigational agent MK-7240 was associated with higher clinical remission rates than placebo in participants with moderately to severely active ulcerative colitis. According to the authors, a phase 3 study will be initiated to confirm the results of the current study.
3. Digital intervention relieves symptoms and improves QoL in IBS
   A digital health application reduced symptoms and improved quality of life in participants with irritable bowel syndrome (IBS), a randomised controlled trial demonstrated. According to the authors, this tool may provide benefits for patients with IBS, reducing the need for intervention from a healthcare practitioner.
4. Epinephrine boosts efficiency in gastric ESD
   Epinephrine, known for its vasoconstrictive properties, is commonly used for managing haemorrhage. A recent international study explored the efficacy of an epinephrine-enhanced solution in the endoscopic submucosal dissection (ESD) of early gastric cancer treatment. The objective was to determine if epinephrine could optimise ESD procedures by shortening operational times and reducing intra-operative bleeding.
5. Apraglutide: advancing the treatment of short bowel syndrome
   A recent study has unveiled the potential of apraglutide in managing short bowel syndrome with intestinal failure and colon-in-continuity (SBS-IF-CiC). This research offers hope for patients grappling with the challenges of short bowel syndrome, a rare gastrointestinal condition marked by a high risk of developing intestinal failure.
6. Obefazimod takes the spotlight as promising UC treatment
   Obefazimod displayed ongoing efficacy over 2 years of treatment in participants with moderately to severely active ulcerative colitis in an open-label phase 2b study. The investigational agent was well tolerated, and no worrisome safety signals were observed.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers



Posted on 30 October 202327 June 2024